Anne Marie Simon Barfoed – Sound Bioventures

All Events Fund articles Fund PR News Portfolio articles Portfolio PR

Earthquakes, investing in drugs, and how to be decent in Venture Capital.

Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series. The discussion included Johan’s journey from scientist to seasoned life science investor, the importance of risk management, why a portfolio approach is key when you invest in ...

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

Stockholm, Sweden and Washington D.C., USA – 17 April 2024 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic vi ...

Beyond fundraising: how do venture capitals build early-stage biotechs?

It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant role in building the company with its founders. To better understand the dynamic between biotech startups and VCs, we talked to Johan […]

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.

Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Potential to Treat Many Autoimmune Diseases without Causing Immunosuppression. Autoimmune Diseases Remain a Significant Unmet Medical Need, affecting Millions ...

VC Investing in Clinical Stage Biotherapeutics Companies in Europe and the U.S.

In this episode of Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Bibhash Mukhopadhyay, Managing Partner, Sound Bioventures, a venture capital fund that invests in about-to-be clinical or clinical stage private companies in Europe and the U.S. developing therapies in specialty therapeuti ...

Sound Bioventures 2023 year in review

A busy year with the final close of Sound Bioventures Fund I 2023 was a busy year for Sound Bioventures with the final close of Sound Bioventures Fund I taking the final total capital commitments to Fund I to €116m. We continued to build our portfolio with investments in four new companies and further expanded […]

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

• Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of ...

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing a New Approach to Address Autoimmune Diseases Globally Nearly 125 Million People Live with Psoriasis CAMBRIDGE, Mass., Nov. 9, 2023 /PRNewswire/ — Artax Biopharma ...

Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year

Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory Role Additional Promotions Include Dr. Andre Hoekema to Board Chair, Dr. Maria Nichol to Chief Business Officer Company Expecting AX-158 Phase 2a Psoriasis Trial Safety, Efficacy Results in Second Half of 2024Cambridge, MA, January 04, 2024 – Artax Biopharma, Inc ...

J.P Morgan 42nd Annual Healthcare Conference

🌐Sound Bioventures will be in San Francisco between the 8-11 January attending the J.P Morgan 42nd Annual Healthcare Conference. This event, and the many other events and receptions that week, offer the opportunity to connect with our portfolio companies, our peers and colleagues within the investment community and a wide spectrum of leading biopha ...

The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health

Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Breye Therapeutics ApS announced their collaboration to develop the P2X7 receptor antagonist programme. Breye Therapeutics, a clinical-stage pharmaceutical co ...